This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
A quick reference guide that outlines what you need to know about starting appropriate patients on CIBINQO
Skin clearance and itch reduction were studied with and without TCS
Studied in 1623 adults with moderate-to-severe AD
Have a product question? Request a call from your product representative
CIBINQO is a once-daily oral treatment option
CIBINQO is a JAK inhibitor
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2022 Pfizer Inc. All rights reserved.